[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"photodynamic-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:photodynamic-therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,75,102,126,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100575911","phase-2-the-effect-of-topical-imipramine-on-photodynamic-therapy-mediated-immunosuppression-on-forearms-or-face-on-us-veterans-100575911",false,"NCT06778434","The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans","Acid Sphingomyelinase Inhibition to Mitigate the Environmental Exposure Risks of Ultraviolet Light-Induced Actinic Neoplasia and Squamous Cell Carcinoma in US Veterans","Inclusion Criteria:\n\n* Adult Males and Females ages 18 and older who are patients at the Dayton VAMC Dermatology clinics\n* Skin type must be \"Fair\", Fitzpatrick type I or II, due to the presence of actinic damage in this population.\n* Subjects must have a VA physician's order to receive PDT treatment on their forearms.\n* Willing to participate and understand the informed consent document.\n* Willing to avoid excess sun exposure\u002Ftanning beds to the area to be treated with PDT.\n* Has stable transportation to attend study visits at DVA\n\nExclusion Criteria:\n\n* Currently taking any tricyclic antidepressants (TCAs)\n* Currently taking any selective serotonin reuptake inhibitor (SSRI)\n* Has Porphyria\n* Large tattoos in areas to be tested\n* Pregnancy or nursing\n* Taking any oral or topical medications that could interfere with the PDT\n* Active rashes in the areas","ALL","18 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to test the use of topical imipramine in combination with topical photodynamic therapy's (PDT) effect on the effectiveness and pain immunosuppression following treatment. PDT is a commonly used treatment in dermatology for patients who have many pre-cancers (actinic keratosis or \"AK\") on their skin. These are both FDA-approved medications, but this study is evaluating their use in combination, which has not been evaluated in the past. The investigators have been doing studies using mice that suggest imipramine might reduce immune system suppression by PDT thus allowing it to work better. Subjects whose provider has decided that they may benefit from PDT to treat their skin due to many AK precancerous lesions will be recruited for this study. Please note that the PDT itself is not experimental, only the imipramine treatment to the skin. There is a separate informed consent for the PDT.",[26,27,28],"Actinic Keratosis","Imipramine","Photodynamic Therapy","RECRUITING","2025-12-18",{"date":32,"type":33},"2025-12-22","ACTUAL",{"date":35,"type":33},"2025-04-01",{"date":37,"type":20},"2029-03-30",{"name":39,"class":40},"VA Office of Research and Development","FED",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":41},"100520089","comparison-of-5-ala-photodynamic-therapy-and-co2-laser-for-treating-persistent-low-grade-cervical-lesions-with-high-risk-hpv-infection-100520089","NCT06052033","Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection","The Effect of 5-aminolaevulinic Acid Photodynamic Therapy Versus C02 Laser in the Treatment of Persistent Cervical Low-grade Squamous Intraepithelial Lesions With High-risk HPV Infection:A Non-randomized Controlled Trail Study","Inclusion Criteria:\n\n1. Aged 18-65 years old with a history of sexual activity.\n2. Subclinical infected individuals who have been confirmed as HR-HPV positive (if there is the same positive type in the typing test) for more than 1 year using HPV typing test, HPV E6\u002FE7 mRNA test, HPV DNA test, and cervical triple step diagnostic procedure (cytology colposcopy histopathology).\n3. Patients diagnosed with LSIL by pathological examination of cervical biopsy under colposcopy with an interval of more than 1 year.\n4. No fundamental diseases of important organs.\n5. Agree to receive treatment and\u002For follow-up according to regulations and sign an informed consent form.\n6. There has been no history of using other drugs related to HPV infection in the past 3 months.\n\nExclusion Criteria:\n\n1. HR-HPV persistent infection.\n2. A total hysterectomy has been performed.\n3. Concomitant endometrial cancer, ovarian cancer, and other reproductive tract tumors.\n4. Complicated with abnormal heart, liver, and kidney functions, immune dysfunction, or immune system diseases such as systemic lupus erythematosus (SLE).\n5. Using drugs such as immunosuppressants, antiviral agents, and glucocorticoids.\n6. Pregnant and lactating women.\n7. Acute reproductive tract inflammation.\n8. Diabetes patients with uncontrolled blood sugar.\n9. Patients who do not receive full treatment and follow-up.\n10. Those who fail to sign the informed consent form.","FEMALE","65 Years",{"count":52,"type":20},40,[54],"NA","Non-RCT clinical trial comparing 5-ALA photodynamic therapy and CO2 laser for persistent high-risk HPV-related low-grade cervical lesions.",[57,58,59,28],"HPV-Related Cervical Carcinoma","Low-Grade Squamous Intraepithelial Lesions","HPV Infection",[61,62,63,64],"high-risk hpv infection","hpv persistent","Lsil","cervical lesions","2025-05-12",{"date":67,"type":33},"2025-05-13",{"date":69,"type":33},"2023-09-11",{"date":71,"type":20},"2025-06-30",{"name":73,"class":74},"First Affiliated Hospital of Wenzhou Medical University","OTHER",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":41},"100550332","photodynamic-therapy-with-hydrogel-dressing-for-chronic-wounds-100550332","NCT06445699","Photodynamic Therapy With Hydrogel Dressing for Chronic Wounds","Investigation the Clinical Effectiveness of Combination Topical Aminolaevulinic Acid-Photodynamic Therapy With Hydrogel Dressing for Treatment Chronic Cutaneous Wounds","Inclusion Criteria:\n\n* 1\\) patients with chronic wounds caused by trauma or surgery who failed to heal after traditional formal medical treatment at least over three months;\n* 2\\) Patients with stable vital signs who had no systemic medical disease and did not take glucocorticoids, immunosuppressive agents, or anticoagulants during the entire treatment process;\n* 3\\) Participants provided signed informed consent, were able to comply with the program, were willing to participate in follow-up, and were able to cooperate in the observation of adverse events and efficacy;\n* 4\\) The diameter of the skin wound should not exceed 10 centimeters.\n\nExclusion Criteria:\n\n* 1\\) Patients are allergic to ALA;\n* 2\\) Women with recent fertility, pregnancy or lactation plans;\n* 3\\) Patients with deepening wounds or worsening infections;\n* 4\\) Poor compliance leading to an inability to complete the treatment in its entirety;\n* 5\\) Cutaneous ulcer caused by vascular disease, autoimmune diseases, metabolic diseases, local or metastatic malignant tumors.","70 Years",{"count":84,"type":20},69,[54],"63 patients with chronic infectious wounds were enrolled in the controlled study. They were randomly divided into three groups equally. Group 1 (Grp.1): The patients received hydrogel dressing change at three days intervals. Group 2 (Grp.2): The patients received ALA-PDT treatment at ten days intervals for 4 sessions. Groups 3 (Grp.3): The patients received ALA-PDT at ten days intervals for 4 sessions combined with hydrogel dressing change every three days intervals. The wound healing rate, total effective rate, patient satisfaction, adverse reaction, and recurrence were assessed in all groups.",[28],[89,90,91,92],"Wound healing","Aminolaevulinic acid","Photodynamic therapy","Hydrogel dressing","2024-07-29",{"date":95,"type":33},"2024-07-30",{"date":97,"type":33},"2023-01-01",{"date":99,"type":20},"2024-08",{"name":101,"class":74},"Army Medical University, China",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100552088","combination-of-micropulse-laser-with-or-without-photodynamic-therapy-for-chronic-central-serous-chorioretinopathy-100552088","NCT06468540","Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy","Comparative Study on the Efficacy of the Combination of Micropulse Laser With or Without Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinal Disease","Inclusion Criteria:\n\n* Age \\>18 years old.\n* The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula.\n* Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment.\n* Patients had follow-up data before and after treatment for 1 month and at least 6 months.\n\nExclusion Criteria:\n\n* Patients with other fundus diseases or refractive interstitial opacity.\n* During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received.\n* Various reasons led to incomplete patient data.",{"count":110,"type":20},60,"OBSERVATIONAL","In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.",[114,115,28],"Central Serous Chorioretinopathy","Micropulse Laser","NOT_YET_RECRUITING","2024-06-15",{"date":119,"type":33},"2024-06-21",{"date":117,"type":20},{"date":122,"type":20},"2025-12-15",{"name":124,"class":125},"Beijing Hospital","OTHER_GOV",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":41},"100492189","phase-1-the-effect-of-topical-imipramine-on-pain-and-effectiveness-of-topical-photodynamic-therapy-100492189","NCT05688904","The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy","Pilot Studies Testing the Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy","Inclusion Criteria:\n\n* Male or female ages 18 and older\n* Skin type must be \"Fair\", Fitzpatrick type I to III, due to the presence of actinic damage in this population.\n* Subjects need to have a physician's order to receive PDT treatment on their face, scalp or forearms.\n* Willing to participate and understand the informed consent document.\n* Willing to avoid excess sun exposure\u002Ftanning beds to the area to be treated with PDT.\n\nExclusion Criteria:\n\n* Those currently taking any tricyclic antidepressants (TCAs)\n* Those currently taking any selective serotonin reuptake inhibitor (SSRI)\n* Those with porphyria\n* Large tattoos in the treated areas\n* Pregnancy or nursing\n* Taking any oral or topical medications that could interfere with the PDT (Appendix A)\n* Active rashes in the area",{"count":134,"type":20},24,[136],"PHASE1","The purpose of this study is testing the use of topical Imipramine in combination with topical photodynamic therapy's (PDT) effect on pain following treatment. PDT is a commonly used treatment in dermatology for patients who have many pre-cancers (actinic keratosis-AKs) on their skin. These are both FDA-approved treatments, but this study is evaluating their use in combination, which has not been evaluated in the past. The investigators have been doing studies using animals that suggest that imipramine might make the PDT less painful and might help it work better. In order to participate, the subject and their dermatologist have decided that they would benefit from PDT to treat their skin due to many AK precancerous lesions. Please note that neither PDT nor imipramine are experimental treatments, but treating their skin with imipramine before PDT is a new approach.",[27,28,26],"2024-04-23",{"date":141,"type":33},"2024-04-24",{"date":143,"type":33},"2023-01-19",{"date":145,"type":20},"2028-03",{"name":147,"class":74},"Wright State University",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":21,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":41},"100540057","phase-2-study-to-evaluate-the-efficacy-safety-and-tolerability-of-photodynamic-therapypdt-with-chlorin-e6-in-treating-moderate-to-severe-acne-100540057","NCT06311890","Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne","Inclusion Criteria:\n\n1. Subject is male or non-pregnant female 18 years of age and younger than 50 years of age.\n2. Subject has moderate to severe facial acne vulgaris.\n3. Subject has provided written informed consent.\n\nExclusion Criteria:\n\n1. People who are taking photosensitive drugs;\n2. Allergic to any component of the photosensitizer;\n3. porphyrins or allergies to porphyrins, with a history of photosensitivity;\n4. Pregnant or lactating women and those planning to become pregnant within 3 months;\n5. Oral or topical antibiotics, retinoids, glucocorticoids, peroxybenzoyl and other drugs within the past 1 month;\n6. Have a history of exposure to sunlight in the past 1 month, have received photoelectric treatment in the past 3 months, or have received facial grinding treatment in the past six months;\n7. are using vasodilators (such as nitroglycerin, etc.), beta blockers (such as metoprolol, etc.), anticoagulants (such as warfarin, etc.) and other drugs that easily cause facial capillary dilatation;\n8. Patients with facial rosacea, atopic dermatitis, hormone-dependent dermatitis and other facial skin-related diseases;\n9. Abnormal blood and urine routine, liver and kidney function, diseases of important organs and hematopoietic system that researchers believe are not suitable for clinical trials;\n10. Patients participating in other clinical trials at the same time.","50 Years",{"count":156,"type":20},46,[23],"This study aims to evaluate the clinical efficacy, safety and tolerability of a photodynamic therapy(PDT) based on a new photosensitizer, Chlorin-e6, in the treatment of moderate to severe acne. The hypothesis is that the therapy has good efficacy, safety and tolerability.",[160,28],"Acne","2024-03-13",{"date":163,"type":33},"2024-03-15",{"date":165,"type":33},"2024-02-01",{"date":167,"type":20},"2026-09-30",{"name":169,"class":74},"Xiyuan Hospital of China Academy of Chinese Medical Sciences"]